Stephen Willard
Vermögen: 595 738 $ am 31.05.2026
Vermögen: 595 738 $ am 31.05.2026
Stephen H.
Willard is Chief Executive Officer & Director at Longeveron, Inc. since 2026.
Mr. Willard is Director at Global Life Technologies Corp.
Mr. Willard is Director at The National Science Board since 2018.
Former roles include Chief Executive Officer & Director at Cellphire, Inc. from 2013 to 2021; Chief Executive Officer & Secretary at NRX Pharmaceuticals, Inc. in 2024; Executive Director at Nozin, Inc. from 2021 to 2022; Non-Executive Chairman at Flamel Technologies SA from 2012 to 2014; Independent Director at E*TRADE Financial Corp.
from 2012 to 2014; Director at E*TRADE Bank from 2000 to 2014; Director at ETB Holdings, Inc. in 2005; Associate Director-Resolutions at Federal Deposit Insurance Corp.
from 1991 to 1994; Chief Executive Officer at Icapath, Inc.; and President at Flamel Technologies, Inc. Education includes graduate degree from Yale University in 1985 and undergraduate degree from Williams College in 1982.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LONGEVERON INC. CLASS A 2,56 % | 01.07.2026 | 771.681 ( 2,56 % ) | 595 738 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LONGEVERON INC. | Vorstandsvorsitzender | 11.02.2026 |
Global Life Technologies Corp.
Global Life Technologies Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Direktor/Vorstandsmitglied | - |
The National Science Board | Direktor/Vorstandsmitglied | 01.01.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
Icapath, Inc.
Icapath, Inc. Miscellaneous Commercial ServicesCommercial Services Develops drug delivery technology that combines PLGA nanoparticles | Vorstandsvorsitzender | 01.10.2025 |
| NRX PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 11.10.2024 |
Cellphire, Inc.
Cellphire, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotechnology company that develops platelet-derived therapeutics | Vorstandsvorsitzender | 01.03.2021 |
Flamel Technologies SA
Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Vorsitzender | 02.07.2014 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 14 |
|---|---|
E*TRADE Financial Corp.
E*TRADE Financial Corp. Investment Banks/BrokersFinance Provides online stock brokerage and investing services | Finance |
Flamel Technologies SA
Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Health Technology |
E*TRADE Bank
E*TRADE Bank Regional BanksFinance Provides banking services | Finance |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Williams College
Williams College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Federal Deposit Insurance Corp.
Federal Deposit Insurance Corp. Insurance Brokers/ServicesFinance Operates as an insurance agency | Finance |
ETB Holdings, Inc.
ETB Holdings, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Flamel Technologies, Inc. | |
The National Science Board | |
Cellphire, Inc.
Cellphire, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotechnology company that develops platelet-derived therapeutics | Commercial Services |
Longeveron, Inc.
Longeveron, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops cellular therapies for aging-related and life-threatening conditions | Health Technology |
Global Life Technologies Corp.
Global Life Technologies Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
NRX Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a molecule pharmaceutical company | Health Technology |
Icapath, Inc.
Icapath, Inc. Miscellaneous Commercial ServicesCommercial Services Develops drug delivery technology that combines PLGA nanoparticles | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen